
|Articles|January 1, 2004
Adjustability a plus for microkeratomes
Author(s)Lynda Charters
Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Detecting peripheral retinal lesions in children with myopia
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD
5


























